You must be signed in to use this feature.





Chair: Bruce A. Chabner, MD

This annual Colloquium is held in collaboration with The Massachusetts General Hospital Cancer Center and designed to focus on topics that bring cancer biology to clinical application:

  • New targets and targeted agents
  • Strategies for profiling and selection of patients for targeted drug trials
  • Biomarkers and animal models to guide clinical development

Learning Objectives

As a result of participating in this activity, participants should be able to:

  • Better delineate new cancer-targeting pathways and potential agents for treatment of malignant disease.
  • Identify patients who would benefit from targeted cancer therapy, especially those patients who should consider enrollment in clinical trials.
  • Distinguish new and emerging biomarkers that may better identify patients with cancer who would benefit most from targeted therapies.

Competencies to be addressed

Patient Care • Medical Knowledge • Systems-based Practice • Professionalism • Interpersonal and Communication Skills

Who Should Attend?

This activity is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

Agenda - pdf


Accreditation/ Credit Designation

The Society for Translational Oncology (STO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society for Translational Oncology designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

The Society for Translational Oncology gratefully acknowledges support of this activity from:

Amgen, Inc.
EMD Serono, Inc.
Janssen R&D, LLC
Novartis Pharmaceuticals Corp.

Commercial support from industry does not influence educational content, faculty selection, and/or presentations.

The Oncologist Young Investigator Award Ceremony
November 5th, 2018 from 5:30pm-5:45pm at the conclusion of the Colloquium.

Disclosure Statement

It is the policy of the Society for Translational Oncology to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial interests and other relationships. The faculty members have been made aware of their obligation to disclose any references to unlabeled uses of FDA-approved products or to products not approved by the FDA for us in the United States. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices. Any discussions of off-label product usage are not endorsed by STO or the meeting directors.

Closing Event

At the conclusion of the scientific sessions, enjoy lite hors d’oeuvre, cocktails and an exhibit review while you exchange scientific ideas with both new and old friends. Each attendee will receive a ticket to the closing reception with their meeting registration. Badges and celebration tickets are required to attend this event.

Cancellation Policy

Refunds, less an administrative fee of $25 will be issued for all cancellations received in writing at least two weeks prior to the start of the meeting. No refund will be issued for cancellations that occur less than two weeks prior. No Shows are subject to the full meeting fee.

Americans with Disabilities (ADA)

If disability accommodations (e.g., communication access, alternate formats) are needed to participate fully in this event, please contact Carol Hardman at 919.433.0489 and carol.hardman@sto-online.org.

For CME questions, please contact: STO at carol.hardman@sto-online.org.